Clobazam

Benzodiazepine — NERVOUS SYSTEM

Key facts

Clobazam is an ofp drug in the Benzodiazepine class catalogued in DrugCentral. It was first approved by the FDA in 2011. Its mechanism of action is classified as Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A4 Inducers. DrugCentral lists 1 molecular target, including GABRA1|GABRG2|GABRB2. Recorded indications include Lennox-Gastaut syndrome.

• Approval status: ofp (first approved 2011 by the FDA).
• Drug class: Benzodiazepine.
• Mechanism of action: Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inducers.
• Molecular targets: GABRA1|GABRG2|GABRB2 (1 listed in DrugCentral).
• Indications: Lennox-Gastaut syndrome.
• ATC code: N05BA09 (Benzodiazepine derivatives).
• Molecular formula: C16H13ClN2O2; molecular weight 300.74 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Lennox-Gastaut syndrome

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2D6 Inhibitors; Cytochrome P450 3A4 Inducers
• Established pharmacologic class: Benzodiazepine

Molecular targets (1)

Target	Gene	Action	Activity
GABA-A receptor alpha-1/beta-2/gamma-2	GABRA1|GABRG2|GABRB2	positive allosteric modulator	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2011-10-21	FDA	—	LUNDBECK LLC	Yes

ATC classification

ATC code	Therapeutic hierarchy
N05BA09	NERVOUS SYSTEM › PSYCHOLEPTICS › ANXIOLYTICS › Benzodiazepine derivatives

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2C19 · Actionable PGx
• HCSC label: CYP2C19 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Seizure	5315.6
Multiple-drug resistance	1771.2
Status epilepticus	1676.1
Somnolence	1639.8
Generalised tonic-clonic seizure	1008.2
Epilepsy	959.4
Drug ineffective	955.1
Aggression	766.3
Petit mal epilepsy	714.9
Drug interaction	677.0
Drug withdrawal convulsions	675.4
Partial seizures	635.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Clobazam is on its molecule page.

• Molecular formula: C₁₆H₁₃ClN₂O₂
• Molecular weight: 300.74 g/mol
• CAS number: 22316-47-8
• InChIKey: CXOXHMZGEKVPMT-UHFFFAOYSA-N
• PubChem CID: 2789

CN1C2=CC=C(Cl)C=C2N(C2=CC=CC=C2)C(=O)CC1=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Clobazam used for?

DrugCentral lists the following indications for Clobazam: Lennox-Gastaut syndrome.

How does Clobazam work?

Clobazam is classified as Cytochrome P450 2D6 Inhibitors and Cytochrome P450 3A4 Inducers; its molecular targets in DrugCentral include GABRA1|GABRG2|GABRB2 (positive allosteric modulator).

When was Clobazam first approved?

Clobazam was first approved by the FDA in 2011.

What drug class does Clobazam belong to?

Clobazam is in the Benzodiazepine class.

What is the chemical formula of Clobazam?

Clobazam has the molecular formula C16H13ClN2O2 and a molecular weight of 300.74 g/mol.

Sources

• DrugCentral drug card 682 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL70418 — compound record and bioactivity
• PubChem CID 2789 — chemical identifiers
• DrugBank DB00349 — drug record
• FDA UNII 2MRO291B4U — substance identity
• DailyMed: FDA labels for Clobazam — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.